励晶太平洋(00575.HK)将获万邦医药支付里程碑款项至少288万美元
励晶太平洋(00575.HK)公布,获复星医药(02196.HK)旗下江苏万邦生化医药通知,产品Senstend已於2月5日取得药品审评中心之临床试验审批,为产品的重要里程碑,万邦医药因此须向公司支付预扣税前款项 320万美元,或预扣税後288万美元。
励晶太平洋表示,现时将尽全力展开随机化临床试验工作,该计划将於4月至5月份开始,预计12个月内完成,江苏万邦医药已委聘一间合同研究机构进行第三期双盲多中心随机化临床试验。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.